The real danger of lamivudine‐resistant hepatitis B virus infection in the immunocompromised host

Hugo E. Vargas – 30 December 2003 – In many transplant centres lamivudine is an important component of prophylaxis against, and treatment of, hepatitis B virus (HBV) graft infection. Drug resistant HBV species with specific polymerase mutations may emerge during lamivudine treatment. Aims: To examine the clinical consequences of graft infection by lamivudine resistant virus. Methods: The clinical course of four liver transplant patients who developed graft infection with lamivudine resistant virus was reviewed.

Improvement of hepatorenal syndrome with extracorporeal albumin dialysis mars: Results of a prospective, randomized, controlled clinical trial

Steffen R. Mitzner, Jan Stange, Sebastian Klammt, Teut Risler, Christiane M. Erley, Brigitte D. Bader, Elke D. Berger, Werner Lauchart, Piotr Peszynski, Jens Freytag, Heiko Hickstein, Jan Loock, Johannes‐Mathias Löhr, Stefan Liebe, Jörg Emmrich, Gero Korten, Reinhard Schmidt – 30 December 2003 – In hepatorenal syndrome (HRS), renal insufficiency is often progressive, and the prognosis is extremely poor under standard medical therapy.

Rapid method for the analysis of peripheral chimerism in suspected graft‐versus‐host disease after liver transplantation

Amy B. Hahn, Prabhakar Baliga – 30 December 2003 – The effects of microchimerism and possible tolerance have been well studied in orthotopic liver transplantation. In some patients, greater levels of donor cells persist in the periphery. These cells were characterized and their effects on clinical outcome were studied. Peripheral blood was obtained from patients at various times posttransplantation. HLA class II typing was performed by the polymerase chain reaction–sequence‐specific primer method on unfractionated blood and lymphocyte subpopulations.

Hepatocyte transplantation in acute liver failure

Bahri M. Bilir, Denis Guinette, Fritz Karrer, David A. Kumpe, Joe Krysl, Janet Stephens, Loris McGavran, Alina Ostrowska, Janette Durham – 30 December 2003 – The majority of patients with acute liver failure (ALF) die waiting for orthotopic liver transplantation (OLT). No other treatment modality is shown to improve survival. This study was conducted to assess the safety and feasibility of hepatocyte transplantation (HT) and subsequent engraftment and function of donor cells.

Subscribe to